Plain-English translation of NCT06446726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment for advanced esophageal cancer that hasn't yet been treated. The treatment combines three approaches: low-dose radiation therapy, chemotherapy drugs ( and ), and an immunotherapy medication called . The goal is to shrink the tumor before surgery so you have the best possible outcome.
Esophageal cancer in China is often diagnosed at an advanced stage, and survival rates remain poor even with current treatments. Recent research shows that adding immunotherapy to chemotherapy before surgery may help more patients achieve complete tumor response, but doctors want to study whether combining it with low-dose radiation could work even better.
You likely qualify if…
You likely don't qualify if…
You would receive two cycles of treatment, each lasting 21 days. In each cycle, you'll receive low-dose radiation on two or three days, followed by an infusion of the immunotherapy medication and two chemotherapy drugs on another day. After completing both cycles (about 6 weeks), you'll have surgery to remove the tumor. The trial involves regular clinic visits for treatment and monitoring, blood tests, and imaging scans to check how the tumor is responding.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China